COMP <GO>
ZYBT vs RNXT // ALTMAN Z-SCORE & DEBT/EQUITY
Zhengye Biotechnology Holding Limited (Class A) (NASDAQ) VS. RenovoRx Inc. (NASDAQ) • 15-METRIC TALLY: ZYBT 4
— RNXT 3
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ZYBT
LAST: $1.30 (-9.09%) • MKT CAP: $67.8M
balance-sheet
1.90
LAST: $1.33 (-10.74%) • MKT CAP: $67.2M
balance-sheet
0.40
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZYBT VS. RNXT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZYBT | RNXT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 20.50% | 70.90% | -50.40 | RNXT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -22.30% | -35.00% | +12.70 | ZYBT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.61% | -16.32% | +18.93 | ZYBT | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -34.80% | 180.00% | -214.80 | RNXT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 1.90 | 0.40 | +1.50 | ZYBT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 4/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.1 | 47.1 | -4.02 | RNXT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $67.8M | $67.2M | $526.7K | ZYBT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZYBT REV | RNXT REV | ZYBT GROSS % | RNXT GROSS % | ZYBT FCF | RNXT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $16.6M | $1.1M | 20.5% | 70.9% | $1.8M | -$11.0M |
| FY 2024 | $25.5M | $43.0K | 49.0% | 98.0% | $3.8M | -$9.1M |
| FY 2023 | — | $0 | — | — | — | -$10.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZYBT // BETA —
RNXT // BETA —